Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Lantmännen in conjunction with acquisition from Tate&Lyle
Mandate

Vinge advises Lantmännen in conjunction with acquisition from Tate&Lyle

March 28, 2019 M&A

Vinge has advised Lantmännen in connection with its acquisition of British Tate&Lyle’s Swedish oat production operations.

The acquisition is a part of Lantmännen’s continued focus on additional processing of oats to, inter alia, the food manufacturing industry.

Vinge’s team consisted of partner Christina Kokko together with, among others, associates Karl Klackenberg and David Lundahl (M&A), partner Johan Cederblad and associate Hampus Olsson (Environmental/Permits) as well as associates Hedvig Ekdahl (Commerical Agreements), Lisa Ullman (Employment), Karolina Cohrs (Real Property) and Klara Secher (IP).
 

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

 Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

 Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

 Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026